Richter, Joshua <br/><br/>
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.  [electronic resource] 

 -  Blood  Jan 2013 
 - 423-30 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2012-06-435503  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Combined Modality Therapy<br/>Dendritic Cells--cytology<br/>Drug Synergism<br/>Female<br/>Galactosylceramides--metabolism<br/>Humans<br/>Killer Cells, Natural--drug effects<br/>Lenalidomide<br/>Lymphocyte Activation--drug effects<br/>Male<br/>Middle Aged<br/>Monocytes--cytology<br/>Multiple Myeloma--drug therapy<br/>Thalidomide--analogs & derivatives<br/>Treatment Outcome